Panelists discuss how significant gaps in current uncomplicated urinary tract infection (UTI) therapies include insufficient nonantibiotic preventive strategies, limited options for ...
But what if they could even help reduce the prevalence of breast cancer? To conduct the analysis, researchers looked at the ...
Breast cancer is a pervasive health concern that affects women globally, but its impact varies significantly across different demographics. Among these, Black women face unique challenges that ...
Patients with stage I HER2-positive breast cancer treated with rastuzumab emtansine (T-DM1) had beneficial long-term outcomes with a 5-year disease-free survival rate of 97%, with the HER2DX score ...
In a recent study, obesity was linked to an increased risk of recurrence for patients with HR-positive, early-stage breast cancer. Obesity was associated with an increased recurrence risk for patients ...
The likelihood of EGFR-positive lung cancer returning is largely tied to how advanced it is when first diagnosed, with lower chances in early stages and higher odds in later stages. Newer targeted ...
Influence of Epithelial-Mesenchymal Transition on Risk of Relapse and Outcome to Eribulin or Cyclin-Dependent Kinase Inhibitors in Metastatic Breast Cancer We retrospectively identified patients from ...
Multiomic Characterization of RCC1 and RCC2 Expression and Their Association With Molecular Alterations, Immune Phenotypes, and Cancer Outcomes This retrospective analysis included patients with ...
MUSC Hollings Cancer Center researchers have unlocked a discovery that could help to explain why cancer can recur in patients who have undergone chemotherapy or radiotherapy. Both types of therapy put ...
Patients with HER2-positive breast cancer in the FLAMINGO-01 phase 3 clinical trial are seeing a continued reduction in recurrence rates, Greenwich LifeSciences, Inc. has reported. The preliminary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results